Nora Zizlsperger

1.6k total citations · 1 hit paper
12 papers, 1.2k citations indexed

About

Nora Zizlsperger is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nora Zizlsperger has authored 12 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nora Zizlsperger's work include Cancer Immunotherapy and Biomarkers (5 papers), CAR-T cell therapy research (3 papers) and Advanced Breast Cancer Therapies (2 papers). Nora Zizlsperger is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), CAR-T cell therapy research (3 papers) and Advanced Breast Cancer Therapies (2 papers). Nora Zizlsperger collaborates with scholars based in United States, France and Italy. Nora Zizlsperger's co-authors include J. Schreiber, Graeme I. Bell, George W. Bell, D. Benjamin Gordon, Ernest Fraenkel, Nicola J. Rinaldi, Duncan T. Odom, P. Alexander Rolfe, Richard A. Young and Heather L. Murray and has published in prestigious journals such as Science, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nora Zizlsperger

12 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Control of Pancreas and Liver Gene Expression by HNF Transcription Factors

2004 1.1k citations Duncan T. Odom, Nora Zizlsperger et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nora Zizlsperger United States	10	766	386	269	177	135	12	1.2k
Chuhu Yang United States	12	1.3k 1.8×	244 0.6×	274 1.0×	171 1.0×	117 0.9×	12	1.7k
Wendy Garrison United States	5	508 0.7×	427 1.1×	200 0.7×	151 0.9×	258 1.9×	6	947
Takao Nammo Japan	16	762 1.0×	715 1.9×	516 1.9×	84 0.5×	53 0.4×	32	1.3k
Alexandra A. Henrion France	7	553 0.7×	177 0.5×	106 0.4×	73 0.4×	64 0.5×	7	792
Hanne Cathrine Bisgaard Denmark	23	674 0.9×	485 1.3×	107 0.4×	259 1.5×	504 3.7×	37	1.4k
Sabine Senkel Germany	15	490 0.6×	303 0.8×	232 0.9×	105 0.6×	44 0.3×	22	728
Angus T. De Souza United States	11	759 1.0×	97 0.3×	194 0.7×	239 1.4×	93 0.7×	12	1.1k
Ànna Manzano Spain	22	1.2k 1.5×	277 0.7×	85 0.3×	263 1.5×	110 0.8×	41	1.8k
Robert V. Martinez United States	14	524 0.7×	69 0.2×	105 0.4×	206 1.2×	39 0.3×	22	901
Russell Ericksen United States	14	523 0.7×	184 0.5×	120 0.4×	305 1.7×	23 0.2×	22	1.0k

Countries citing papers authored by Nora Zizlsperger

Since Specialization

Citations

This map shows the geographic impact of Nora Zizlsperger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nora Zizlsperger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nora Zizlsperger more than expected).

Fields of papers citing papers by Nora Zizlsperger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nora Zizlsperger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nora Zizlsperger. The network helps show where Nora Zizlsperger may publish in the future.

Co-authorship network of co-authors of Nora Zizlsperger

This figure shows the co-authorship network connecting the top 25 collaborators of Nora Zizlsperger. A scholar is included among the top collaborators of Nora Zizlsperger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nora Zizlsperger. Nora Zizlsperger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Hamilton, Erika, Hyo S. Han, Kevin Kalinsky, et al.. (2025). Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate.. Journal of Clinical Oncology. 43(16_suppl). 3009–3009. 1 indexed citations

O’Connell, Brenda, Nora Zizlsperger, Donna M. Fitzgerald, et al.. (2024). Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 12(8). e009160–e009160. 32 indexed citations

Hong, David S., Michael A. Postow, Bartosz Chmielowski, et al.. (2023). Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clinical Cancer Research. 29(12). 2210–2219. 48 indexed citations

Hargis, Jeffrey B., Anthony Elias, Rachel Swart, et al.. (2022). Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC). Cancer Research. 82(4_Supplement). P5–16. 12 indexed citations

Tomczak, Piotr, Lazar Popović, Philippe Barthélémy, et al.. (2021). Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma.. Journal of Clinical Oncology. 39(6_suppl). 436–436. 14 indexed citations

Postow, Michael A., Ryan J. Sullivan, Ezra E.W. Cohen, et al.. (2020). 434 Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab. SHILAP Revista de lepidopterología. A264–A265. 10 indexed citations

Cohen, Ezra E.W., Michael A. Postow, Ryan J. Sullivan, et al.. (2020). 352 Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab. Regular and Young Investigator Award Abstracts. A214.2–A215. 9 indexed citations

Klöhn, Peter‐Christian, Nora Zizlsperger, Yu Zhou, et al.. (2013). IBC’s 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society. mAbs. 5(2). 178–201. 11 indexed citations

Zizlsperger, Nora & Amy E. Keating. (2010). Specific coiled-coil interactions contribute to a global model of the structure of the spindle pole body. Journal of Structural Biology. 170(2). 246–256. 6 indexed citations

10.

Zizlsperger, Nora, et al.. (2008). Analysis of Coiled-Coil Interactions between Core Proteins of the Spindle Pole Body. Biochemistry. 47(45). 11858–11868. 19 indexed citations

11.

Allen, Mary M., et al.. (2005). Effects of light and chloramphenicol stress on incorporation of nitrogen into cyanophycin in Synechocystis sp. strain PCC 6308. Biochimica et Biophysica Acta (BBA) - General Subjects. 1725(2). 241–246. 9 indexed citations

12.

Odom, Duncan T., Nora Zizlsperger, D. Benjamin Gordon, et al.. (2004). Control of Pancreas and Liver Gene Expression by HNF Transcription Factors. Science. 303(5662). 1378–1381. 1060 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact